A TVT (tension-free vaginal tape) procedure is a surgical treatment for stress urinary incontinence, the type of leaking that happens when you cough, sneeze, laugh, or exercise. The surgery places a thin strip of synthetic mesh under your urethra to act as a supportive hammock, preventing urine from escaping during moments of physical pressure. First introduced in 1995, it remains one of the most commonly performed surgeries for stress incontinence, with long-term cure rates reaching up to 93%.
How the Procedure Works
The core idea behind TVT is surprisingly simple. Your urethra is held in place partly by ligaments that connect it to surrounding muscles and bone. In women with stress incontinence, that support system has weakened, so the urethra can’t stay closed under pressure. The TVT procedure restores that support by sliding a narrow strip of woven polypropylene mesh (about 45 cm long and just over 1 cm wide) underneath the middle portion of the urethra.
What makes this approach different from older sling surgeries is that the tape isn’t stitched or anchored to any bone, ligament, or muscle. It sits loosely under the urethra with no tension pulling on it. Over time, your body’s tissue grows into the mesh and holds it in place naturally. This tension-free design is what reduces the risk of the common post-surgical problem of difficulty urinating, which older anchored slings caused more frequently.
What Happens During Surgery
The surgery takes about two hours and is performed under either general anesthesia or spinal anesthesia. Your surgeon makes a small incision inside the vaginal wall at the midpoint of the urethra, then separates the tissue to expose the area where the tape will sit. From there, two thin needles guide the mesh upward through the space behind the pubic bone and out through two tiny incisions on the lower abdomen, just above the pubic hairline.
There’s also a variation called the transobturator (TOT) approach, where the tape exits through small incisions on the inner thigh near the groin instead of going behind the pubic bone. The TOT route has a shorter operating time, a lower risk of bladder perforation, and slightly fewer complications overall. However, TVT tends to work better for women whose incontinence stems from a weaker urethral sphincter rather than just poor support, because the retropubic path creates slightly more compression around the urethra. Your surgeon will recommend one route over the other based on your anatomy and the severity of your leaking.
Who Is a Good Candidate
TVT is designed for women with stress urinary incontinence who haven’t gotten enough relief from non-surgical options like pelvic floor exercises or pessaries. It works best when the primary problem is a lack of support under the urethra rather than an overactive bladder muscle.
Certain conditions rule out the retropubic TVT approach entirely. If you’ve had previous surgery behind the pubic bone that may have shifted bowel into that space, or if you have an anatomical variation like a pelvic kidney or a vascular graft in the area, the needle path could cause serious injury. Pregnancy, blood-thinning medication, and hernias in the surgical path are also contraindications. In many of these situations, the transobturator route can be offered instead since it avoids the space behind the pubic bone. Women who’ve had urethral reconstruction surgery or fistula repair are generally not good candidates for either type of sling.
Recovery and Activity Restrictions
Most women go home the same day or the following morning. You can expect to return to desk work or light activity within one to two weeks, but full recovery takes about six weeks. During that time, you’ll need to avoid anything that puts extra pressure on your bladder and pelvic floor while the mesh integrates with your tissue.
For six weeks after surgery, that means no heavy lifting of any kind. This includes grocery bags, milk containers, heavy backpacks, bags of pet food, vacuuming, and picking up children. Strenuous exercise like jogging and weight lifting is off limits, along with straddling activities like cycling or horseback riding. You’ll also need to avoid vaginal intercourse and tampon use for the full six weeks to allow the internal incision to heal.
Success Rates Over Time
Short-term results are strong. Studies report subjective cure rates of up to 93%, meaning that proportion of women feel their incontinence is resolved. Long-term data is more variable. Reoperation rates across 45 analyzed studies ranged from 0% to 19% at five years and 0% to 17% at ten years, depending on the study and the specific sling used. Within the first five years, about 4% of women who received a TVT needed the mesh removed or cut, compared to about 3.25% of women who received the transobturator version.
These numbers reflect a wide range of individual experiences. Some women have decades of complete relief. Others find their incontinence gradually returns, or they develop complications that require further surgery. The likelihood of success depends on factors like the severity of incontinence, body weight, and whether the surgical technique was well matched to the underlying problem.
Risks and Complications
Mesh-related complications occur in roughly 4% of TVT patients, but the rates climb with longer follow-up. Mesh erosion, where the tape works through the vaginal wall and becomes exposed, occurs in up to 6% of women by two years and up to 10% by seven years. Erosion can cause pain, discharge, bleeding, or discomfort during intercourse. In some cases, exposed mesh also becomes infected.
Other risks include bladder perforation during the procedure (more common with TVT than the transobturator route), temporary difficulty emptying the bladder after surgery, and new or worsening urgency. Chronic pain is a less common but well-documented complication. Research on removed mesh implants has found that the body can sustain an inflammatory response around the material for years after implantation, and women whose mesh became exposed showed higher levels of tissue-degrading enzymes compared to women whose primary complaint was pain alone. Lighter-weight mesh with larger pores tends to integrate better and cause less of this inflammatory reaction.
The FDA’s Current Position
It’s worth noting that the FDA’s concerns about surgical mesh have focused primarily on mesh used for pelvic organ prolapse repair, not stress incontinence slings. The FDA effectively banned transvaginal mesh for prolapse in 2019, but mid-urethral slings like TVT remain available. The agency continues to monitor safety reports and recommends that surgeons obtain specialized training for each placement technique, that patients be told mesh is a permanent implant, and that both doctor and patient understand that any future surgical repairs could be more complicated if mesh is already in place.
The FDA also notes that limited long-term outcome data exists beyond one year for many products, and encourages ongoing follow-up to watch for erosion and infection. Newer “mini-sling” designs, which use a shorter piece of mesh and a single incision, have shown comparable effectiveness and similar complication rates to traditional mid-urethral slings through at least three to five years of follow-up.